APO Research
Talk to an analyst

APO RESEARCH · REPORT

FIC Single-target Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global FIC Single-target Drugs Market Outlook and Growth Opportunities 2026

29 December 2025201 pages

Choose your research edition.

Industry ResearchFIC Single-target Drugs Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal FIC Single-target Drugs Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal FIC Single-target Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal FIC Single-target Drugs Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal FIC Single-target Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global FIC Single-target Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for FIC Single-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for FIC Single-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for FIC Single-target Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the FIC Single-target Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the FIC Single-target Drugs market include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Eli Lilly, Pfizer, Polarean lmaging and Phathom, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global FIC Single-target Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of FIC Single-target Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents FIC Single-target Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the FIC Single-target Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

FIC Single-target Drugs Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Eli Lilly

Pfizer

Polarean lmaging

Phathom

Marinus

Mallinckrodt

ImmunoGen

Immunocore

Gilead

Genentech

Dermavant Sciences

Boehringer Ingelheim

BMS

Agios

FIC Single-target Drugs Segment by Type

ALK2 Inhibitors

Citron Inhibitors

GCN2 Agonists

RORγ Covalent Inhibitors

Others

FIC Single-target Drugs Segment by Application

Hospital

Clinic

Other

FIC Single-target Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global FIC Single-target Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions FIC Single-target Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify FIC Single-target Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze FIC Single-target Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global FIC Single-target Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of FIC Single-target Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of FIC Single-target Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the FIC Single-target Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global FIC Single-target Drugs industry.

Chapter 3: Detailed analysis of FIC Single-target Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of FIC Single-target Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of FIC Single-target Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. FIC Single-target Drugs Industry Trends Table 2. FIC Single-target Drugs Industry Drivers Table 3. FIC Single-target Drugs Industry Opportunities and Challenges Table 4. FIC Single-target Drugs Industry Restraints Table 5. Global FIC Single-target Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global FIC Single-target Drugs Revenue Share by Company (2021-2026) Table 7. Global FIC Single-target Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global FIC Single-target Drugs Sales Volume Share by Company (2021-2026) Table 9. Global FIC Single-target Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global FIC Single-target Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global FIC Single-target Drugs Key Company Manufacturing Base & Headquarters Table 12. Global FIC Single-target Drugs Company, Product Type & Application Table 13. Global FIC Single-target Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global FIC Single-target Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ALK2 Inhibitors Table 18. Significant Companies of Citron Inhibitors Table 19. Significant Companies of GCN2 Agonists Table 20. Significant Companies of RORγ Covalent Inhibitors Table 21. Significant Companies of Others Table 22. Global FIC Single-target Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global FIC Single-target Drugs Sales Volume by Type (2021-2026) & (K Units) Table 24. Global FIC Single-target Drugs Sales Volume by Type (2027-2032) & (K Units) Table 25. Global FIC Single-target Drugs Sales Volume Share by Type (2021-2026) Table 26. Global FIC Single-target Drugs Sales Volume Share by Type (2027-2032) Table 27. Global FIC Single-target Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global FIC Single-target Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global FIC Single-target Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global FIC Single-target Drugs Sales Value Share by Type (2021-2026) Table 31. Global FIC Single-target Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Other Table 35. Global FIC Single-target Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global FIC Single-target Drugs Sales Volume by Application (2021-2026) & (K Units) Table 37. Global FIC Single-target Drugs Sales Volume by Application (2027-2032) & (K Units) Table 38. Global FIC Single-target Drugs Sales Volume Share by Application (2021-2026) Table 39. Global FIC Single-target Drugs Sales Volume Share by Application (2027-2032) Table 40. Global FIC Single-target Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global FIC Single-target Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global FIC Single-target Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global FIC Single-target Drugs Sales Value Share by Application (2021-2026) Table 44. Global FIC Single-target Drugs Sales Value Share by Application (2027-2032) Table 45. Global FIC Single-target Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global FIC Single-target Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global FIC Single-target Drugs Sales Market Share by Region (2021-2026) Table 48. Global FIC Single-target Drugs Sales by Region (2027-2032) & (K Units) Table 49. Global FIC Single-target Drugs Sales Market Share by Region (2027-2032) Table 50. Global FIC Single-target Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global FIC Single-target Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global FIC Single-target Drugs Sales Value Share by Region (2021-2026) Table 53. Global FIC Single-target Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global FIC Single-target Drugs Sales Value Share by Region (2027-2032) Table 55. Global FIC Single-target Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global FIC Single-target Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global FIC Single-target Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global FIC Single-target Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global FIC Single-target Drugs Sales by Country (2021-2026) & (K Units) Table 60. Global FIC Single-target Drugs Sales Market Share by Country (2021-2026) Table 61. Global FIC Single-target Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global FIC Single-target Drugs Sales Market Share by Country (2027-2032) Table 63. Global FIC Single-target Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global FIC Single-target Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global FIC Single-target Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global FIC Single-target Drugs Sales Value Market Share by Country (2027-2032) Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Sanofi FIC Single-target Drugs Product Portfolio Table 71. Sanofi Recent Development Table 72. Johnson & Johnson Company Information Table 73. Johnson & Johnson Business Overview Table 74. Johnson & Johnson FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Johnson & Johnson FIC Single-target Drugs Product Portfolio Table 76. Johnson & Johnson Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Novartis FIC Single-target Drugs Product Portfolio Table 81. Novartis Recent Development Table 82. Merck Company Information Table 83. Merck Business Overview Table 84. Merck FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Merck FIC Single-target Drugs Product Portfolio Table 86. Merck Recent Development Table 87. Roche Company Information Table 88. Roche Business Overview Table 89. Roche FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Roche FIC Single-target Drugs Product Portfolio Table 91. Roche Recent Development Table 92. Eli Lilly Company Information Table 93. Eli Lilly Business Overview Table 94. Eli Lilly FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Eli Lilly FIC Single-target Drugs Product Portfolio Table 96. Eli Lilly Recent Development Table 97. Pfizer Company Information Table 98. Pfizer Business Overview Table 99. Pfizer FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Pfizer FIC Single-target Drugs Product Portfolio Table 101. Pfizer Recent Development Table 102. Polarean lmaging Company Information Table 103. Polarean lmaging Business Overview Table 104. Polarean lmaging FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Polarean lmaging FIC Single-target Drugs Product Portfolio Table 106. Polarean lmaging Recent Development Table 107. Phathom Company Information Table 108. Phathom Business Overview Table 109. Phathom FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Phathom FIC Single-target Drugs Product Portfolio Table 111. Phathom Recent Development Table 112. Marinus Company Information Table 113. Marinus Business Overview Table 114. Marinus FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Marinus FIC Single-target Drugs Product Portfolio Table 116. Marinus Recent Development Table 117. Mallinckrodt Company Information Table 118. Mallinckrodt Business Overview Table 119. Mallinckrodt FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Mallinckrodt FIC Single-target Drugs Product Portfolio Table 121. Mallinckrodt Recent Development Table 122. ImmunoGen Company Information Table 123. ImmunoGen Business Overview Table 124. ImmunoGen FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. ImmunoGen FIC Single-target Drugs Product Portfolio Table 126. ImmunoGen Recent Development Table 127. Immunocore Company Information Table 128. Immunocore Business Overview Table 129. Immunocore FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Immunocore FIC Single-target Drugs Product Portfolio Table 131. Immunocore Recent Development Table 132. Gilead Company Information Table 133. Gilead Business Overview Table 134. Gilead FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Gilead FIC Single-target Drugs Product Portfolio Table 136. Gilead Recent Development Table 137. Genentech Company Information Table 138. Genentech Business Overview Table 139. Genentech FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Genentech FIC Single-target Drugs Product Portfolio Table 141. Genentech Recent Development Table 142. Dermavant Sciences Company Information Table 143. Dermavant Sciences Business Overview Table 144. Dermavant Sciences FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Dermavant Sciences FIC Single-target Drugs Product Portfolio Table 146. Dermavant Sciences Recent Development Table 147. Boehringer Ingelheim Company Information Table 148. Boehringer Ingelheim Business Overview Table 149. Boehringer Ingelheim FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Boehringer Ingelheim FIC Single-target Drugs Product Portfolio Table 151. Boehringer Ingelheim Recent Development Table 152. BMS Company Information Table 153. BMS Business Overview Table 154. BMS FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. BMS FIC Single-target Drugs Product Portfolio Table 156. BMS Recent Development Table 157. Agios Company Information Table 158. Agios Business Overview Table 159. Agios FIC Single-target Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. Agios FIC Single-target Drugs Product Portfolio Table 161. Agios Recent Development Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. FIC Single-target Drugs Distributors List Table 165. FIC Single-target Drugs Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. FIC Single-target Drugs Product Image Figure 2. Global FIC Single-target Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global FIC Single-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global FIC Single-target Drugs Sales (2021-2032) & (K Units) Figure 5. Global FIC Single-target Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global FIC Single-target Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ALK2 Inhibitors Image Figure 10. Citron Inhibitors Image Figure 11. GCN2 Agonists Image Figure 12. RORγ Covalent Inhibitors Image Figure 13. Others Image Figure 14. Global FIC Single-target Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global FIC Single-target Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global FIC Single-target Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global FIC Single-target Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global FIC Single-target Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global FIC Single-target Drugs Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Other Image Figure 23. Global FIC Single-target Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global FIC Single-target Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global FIC Single-target Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global FIC Single-target Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global FIC Single-target Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global FIC Single-target Drugs Sales Value Share by Application (2021-2032) Figure 29. Global FIC Single-target Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global FIC Single-target Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global FIC Single-target Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global FIC Single-target Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America FIC Single-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America FIC Single-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe FIC Single-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe FIC Single-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific FIC Single-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific FIC Single-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America FIC Single-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America FIC Single-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa FIC Single-target Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa FIC Single-target Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt FIC Single-target Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. FIC Single-target Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. FIC Single-target Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • ALK2 Inhibitors
  • Citron Inhibitors
  • GCN2 Agonists
  • RORγ Covalent Inhibitors
  • Others
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Polarean lmaging
  • Phathom
  • Marinus
  • Mallinckrodt
  • ImmunoGen
  • Immunocore
  • Gilead
  • Genentech
  • Dermavant Sciences
  • Boehringer Ingelheim
  • BMS
  • Agios

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global FIC Single-target Drugs Sales Value (2021-2032)
  4. 1.2.2 Global FIC Single-target Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global FIC Single-target Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 FIC Single-target Drugs Market Dynamics
  1. 2.1 FIC Single-target Drugs Industry Trends
  2. 2.2 FIC Single-target Drugs Industry Drivers
  3. 2.3 FIC Single-target Drugs Industry Opportunities and Challenges
  4. 2.4 FIC Single-target Drugs Industry Restraints
3 FIC Single-target Drugs Market by Company
  1. 3.1 Global FIC Single-target Drugs Company Revenue Ranking in 2025
  2. 3.2 Global FIC Single-target Drugs Revenue by Company (2021-2026)
  3. 3.3 Global FIC Single-target Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global FIC Single-target Drugs Average Price by Company (2021-2026)
  5. 3.5 Global FIC Single-target Drugs Company Ranking (2024-2026)
  6. 3.6 Global FIC Single-target Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global FIC Single-target Drugs Company Product Type and Application
  8. 3.8 Global FIC Single-target Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global FIC Single-target Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 FIC Single-target Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 FIC Single-target Drugs Market by Type
  1. 4.1 FIC Single-target Drugs Type Introduction
  2. 4.1.1 ALK2 Inhibitors
  3. 4.1.2 Citron Inhibitors
  4. 4.1.3 GCN2 Agonists
  5. 4.1.4 RORγ Covalent Inhibitors
  6. 4.1.5 Others
  7. 4.2 Global FIC Single-target Drugs Sales Volume by Type
  8. 4.2.1 Global FIC Single-target Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global FIC Single-target Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global FIC Single-target Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global FIC Single-target Drugs Sales Value by Type
  12. 4.3.1 Global FIC Single-target Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global FIC Single-target Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global FIC Single-target Drugs Sales Value Share by Type (2021-2032)
5 FIC Single-target Drugs Market by Application
  1. 5.1 FIC Single-target Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global FIC Single-target Drugs Sales Volume by Application
  6. 5.2.1 Global FIC Single-target Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global FIC Single-target Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global FIC Single-target Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global FIC Single-target Drugs Sales Value by Application
  10. 5.3.1 Global FIC Single-target Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global FIC Single-target Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global FIC Single-target Drugs Sales Value Share by Application (2021-2032)
6 FIC Single-target Drugs Regional Sales and Value Analysis
  1. 6.1 Global FIC Single-target Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global FIC Single-target Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global FIC Single-target Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global FIC Single-target Drugs Sales by Region (2027-2032)
  5. 6.3 Global FIC Single-target Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global FIC Single-target Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global FIC Single-target Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global FIC Single-target Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global FIC Single-target Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America FIC Single-target Drugs Sales Value (2021-2032)
  12. 6.6.2 North America FIC Single-target Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe FIC Single-target Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe FIC Single-target Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific FIC Single-target Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific FIC Single-target Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America FIC Single-target Drugs Sales Value (2021-2032)
  21. 6.9.2 South America FIC Single-target Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa FIC Single-target Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa FIC Single-target Drugs Sales Value Share by Country, 2025 VS 2032
7 FIC Single-target Drugs Country-level Sales and Value Analysis
  1. 7.1 Global FIC Single-target Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global FIC Single-target Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global FIC Single-target Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global FIC Single-target Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global FIC Single-target Drugs Sales by Country (2027-2032)
  6. 7.4 Global FIC Single-target Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global FIC Single-target Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global FIC Single-target Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt FIC Single-target Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt FIC Single-target Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt FIC Single-target Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi FIC Single-target Drugs Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson FIC Single-target Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis FIC Single-target Drugs Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck FIC Single-target Drugs Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Roche FIC Single-target Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly
  32. 8.6.1 Eli Lilly Company Information
  33. 8.6.2 Eli Lilly Business Overview
  34. 8.6.3 Eli Lilly FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly FIC Single-target Drugs Product Portfolio
  36. 8.6.5 Eli Lilly Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer FIC Single-target Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Polarean lmaging
  44. 8.8.1 Polarean lmaging Company Information
  45. 8.8.2 Polarean lmaging Business Overview
  46. 8.8.3 Polarean lmaging FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Polarean lmaging FIC Single-target Drugs Product Portfolio
  48. 8.8.5 Polarean lmaging Recent Developments
  49. 8.9 Phathom
  50. 8.9.1 Phathom Company Information
  51. 8.9.2 Phathom Business Overview
  52. 8.9.3 Phathom FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Phathom FIC Single-target Drugs Product Portfolio
  54. 8.9.5 Phathom Recent Developments
  55. 8.10 Marinus
  56. 8.10.1 Marinus Company Information
  57. 8.10.2 Marinus Business Overview
  58. 8.10.3 Marinus FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Marinus FIC Single-target Drugs Product Portfolio
  60. 8.10.5 Marinus Recent Developments
  61. 8.11 Mallinckrodt
  62. 8.11.1 Mallinckrodt Company Information
  63. 8.11.2 Mallinckrodt Business Overview
  64. 8.11.3 Mallinckrodt FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Mallinckrodt FIC Single-target Drugs Product Portfolio
  66. 8.11.5 Mallinckrodt Recent Developments
  67. 8.12 ImmunoGen
  68. 8.12.1 ImmunoGen Company Information
  69. 8.12.2 ImmunoGen Business Overview
  70. 8.12.3 ImmunoGen FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 ImmunoGen FIC Single-target Drugs Product Portfolio
  72. 8.12.5 ImmunoGen Recent Developments
  73. 8.13 Immunocore
  74. 8.13.1 Immunocore Company Information
  75. 8.13.2 Immunocore Business Overview
  76. 8.13.3 Immunocore FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Immunocore FIC Single-target Drugs Product Portfolio
  78. 8.13.5 Immunocore Recent Developments
  79. 8.14 Gilead
  80. 8.14.1 Gilead Company Information
  81. 8.14.2 Gilead Business Overview
  82. 8.14.3 Gilead FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Gilead FIC Single-target Drugs Product Portfolio
  84. 8.14.5 Gilead Recent Developments
  85. 8.15 Genentech
  86. 8.15.1 Genentech Company Information
  87. 8.15.2 Genentech Business Overview
  88. 8.15.3 Genentech FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Genentech FIC Single-target Drugs Product Portfolio
  90. 8.15.5 Genentech Recent Developments
  91. 8.16 Dermavant Sciences
  92. 8.16.1 Dermavant Sciences Company Information
  93. 8.16.2 Dermavant Sciences Business Overview
  94. 8.16.3 Dermavant Sciences FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Dermavant Sciences FIC Single-target Drugs Product Portfolio
  96. 8.16.5 Dermavant Sciences Recent Developments
  97. 8.17 Boehringer Ingelheim
  98. 8.17.1 Boehringer Ingelheim Company Information
  99. 8.17.2 Boehringer Ingelheim Business Overview
  100. 8.17.3 Boehringer Ingelheim FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Boehringer Ingelheim FIC Single-target Drugs Product Portfolio
  102. 8.17.5 Boehringer Ingelheim Recent Developments
  103. 8.18 BMS
  104. 8.18.1 BMS Company Information
  105. 8.18.2 BMS Business Overview
  106. 8.18.3 BMS FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 BMS FIC Single-target Drugs Product Portfolio
  108. 8.18.5 BMS Recent Developments
  109. 8.19 Agios
  110. 8.19.1 Agios Company Information
  111. 8.19.2 Agios Business Overview
  112. 8.19.3 Agios FIC Single-target Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Agios FIC Single-target Drugs Product Portfolio
  114. 8.19.5 Agios Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 FIC Single-target Drugs Value Chain Analysis
  2. 9.1.1 FIC Single-target Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 FIC Single-target Drugs Sales Mode & Process
  6. 9.2 FIC Single-target Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 FIC Single-target Drugs Distributors
  9. 9.2.3 FIC Single-target Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst